What is the recommended dose, administration, and monitoring for Deflazacort (DCort) 30 mg tablets?

Deflazacort (DCort) 30 mg: Dosing, Administration, and Monitoring

For Duchenne muscular dystrophy (DMD), deflazacort 30 mg represents a capped daily dose typically reached when patients weigh approximately 33-40 kg, with the maximum recommended daily dose being 36-39 mg/day regardless of further weight gain. 1

Initial Dosing Strategy

Start deflazacort at 0.9 mg/kg/day for ambulatory DMD patients aged ≥6 years, particularly when pre-existing weight gain or behavioral issues make it preferable to prednisone 1. This translates to:

• A 33 kg patient would receive approximately 30 mg daily
• Maximum cap: 36-39 mg/day once patient reaches ~40 kg 1

Age-Based Initiation

• Age ≥6 years with plateau or declining function: Initiation highly recommended 1
• Age <6 years: Generally not recommended unless atypical decline warrants investigation 1
• Complete immunization schedule before starting, including varicella with protective serum titers 1

Dose Titration Algorithm

For growing children on deflazacort:

1. Increase dose incrementally with growth if side effects remain manageable and tolerable
2. Continue increasing until patient reaches 40 kg body weight
3. Cap at 36-39 mg/day (approximately 30 mg for a 33 kg patient) 1
4. After 40 kg: Allow dose per kilogram to drift down to 0.3-0.6 mg/kg daily range, which still provides substantial benefit 1

Functional Decline Management

If patient shows functional decline while on sub-target dose:

• Increase to target dose (0.9 mg/kg/day)
• Reassess benefit and tolerability in 2-3 months 1

Side Effect Management Protocol

If side effects become unmanageable or intolerable:

1. First step: Reduce daily dose by 25-33% and reassess in 1 month 1
2. If still problematic: Consider additional 25% reduction (minimum effective dose ~0.3 mg/kg/day equivalent) 1
3. For specific issues:
   • Weight gain/behavioral problems: Consider switching to high-dose weekend regimen 1
   • Before abandoning treatment: Try intermittent schedule (0.6 mg/kg days 1-20, then off remainder of month) 1

Critical caveat: Do not increase dose for growth or declining function if side effects are unmanageable—reduction is mandatory 1

Alternative Dosing Regimens (Less Effective)

If daily dosing not tolerated:

• Alternate day: 2 mg/kg every other day 1
• Intermittent: 0.6 mg/kg days 1-20, off remainder of month 1
• High-dose weekend: Not yet tested for deflazacort 1

Monitoring Requirements

Initial 6 Months (Most Critical Period) 1

At each clinic visit:

• Blood pressure (as percentile for height/sex)
• Weight and BMI tracking
• Behavioral assessment
• Urine dipstick for glucose

Annually:

• Ophthalmological examination (cataract screening—deflazacort has higher risk than prednisone) 1
• DEXA scan for bone density 1
• 25-hydroxy vitamin D level (supplement if <32 nmol/L) 1
• Fracture history

Ongoing Surveillance

• Monitor for cushingoid features, growth velocity
• Screen for hypertension (if >99th percentile: reduce salt, consider weight reduction, then ACE inhibitor/β-blocker if needed) 1
• GERD symptoms (prescribe ranitidine or PPI if symptomatic) 1
• Avoid NSAIDs due to peptic ulcer risk 1

Administration Timing

Give once daily in the morning unless behavioral issues (hyperactivity, emotional lability) occur for a few hours post-dose—then consider afternoon administration after school 1

Non-Ambulatory Patients

Continue deflazacort even after loss of ambulation for benefits in:

• Retarding scoliosis progression
• Slowing pulmonary function decline
• Possibly preventing heart failure 1

Maintain at 0.3-0.6 mg/kg daily range (often allowing dose to drift down as weight increases above 40 kg) 1

Key Clinical Pitfalls

1. Do not abandon therapy prematurely: Attempt at least one dose reduction and alternative regimen change before discontinuation 1
2. Cataract risk: Higher with deflazacort than prednisone; if vision-affecting cataracts develop, consider switching to prednisone 1
3. Abrupt discontinuation: Never stop suddenly—ensure steroid alert card and inform all medical personnel 1
4. Dose equivalency confusion: Recent evidence suggests deflazacort may be less potent than traditionally assumed (equipotency ratios vary by endpoint) 2, but FDA-approved dosing remains 0.9 mg/kg/day 3

Note: The evidence provided includes some drug label information for a dental product (fluoride toothpaste) labeled as "DCort" 4, which is unrelated to deflazacort for DMD and should be disregarded.